Last reviewed · How we verify
Lucentis every 12 weeks
Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina.
Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.
At a glance
| Generic name | Lucentis every 12 weeks |
|---|---|
| Sponsor | Retinal Consultants of Arizona |
| Drug class | VEGF-A inhibitor (monoclonal antibody fragment) |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds and neutralizes all active forms of VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF-A signaling, it prevents endothelial cell proliferation and reduces retinal edema, thereby slowing or halting vision loss in conditions characterized by abnormal retinal vasculature.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Diabetic retinopathy
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
Key clinical trials
- Extension Study for the Port Delivery System With Ranibizumab (Portal) (PHASE3)
- A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) (PHASE3)
- Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (PHASE2)
- A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema (PHASE2)
- A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema (PHASE2)
- Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema (PHASE2)
- Ranibizumab and Bevacizumab for Diabetic Macular Edema (PHASE2)
- Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |